Table 3.
Univariate and multivariate analysis of the blood inflammatory biomarkers by dichotomized CRP level (≤1 versus ≥3) and correlation and partial correlation between different blood inflammatory biomarkers with continuous CRP level for the selected recruited subjects.
| Univariate analysis | Multivariate analysis | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Blood marker | Median [interquartile range] | Spearman correlation with continuous CRP | Least square mean (95% CI) | Partial Spearman correlation with continuous CRP | |||||||
| CRP ≤ 1 | CRP ≥ 3 | P value | r | P value | CRP ≤ 1 | CRP ≥ 3 | P value | r | P value | ||
| All Subjects | MCP-1 | 175 [144–216] | 205 [159–296] | 0.08 | 0.16 | 0.16 | 228 (161, 296) | 206 (122, 290) | 0.70 | 0.07 | 0.58 |
| IL-6 | 0.72 [0.45–1.18] | 0.81 [0.48–1.17] | 0.46 | 0.19 | 0.09 | 0.98 (0.71, 1.25) | 1.09 (0.76, 1.42) | 0.62 | 0.25 | 0.03* | |
| sTNF-RI | 842 [716–995] | 875 [725–1238] | 0.13 | 0.17 | 0.13 | 865 (770, 961) | 1005 (887, 1123) | 0.09 | 0.19 | 0.11 | |
| sTNF-RII | 3989 [3153–5187] | 4217 [3670–5172] | 0.34 | 0.24 | 0.04* | 4292 (3899, 4685) | 4324 (3841, 4807) | 0.92 | 0.20 | 0.08 | |
| sCD40L | 2411 [1693–4456] | 3769 [2492–6027] | 0.01* | 0.35 | <0.01* | 3171 (2311, 4031) | 4551 (3493, 5608) | 0.06 | 0.30 | <0.01* | |
|
| |||||||||||
| Nonusers¶ | MCP-1 | 194 [144–216] | 330 [330-330] | 0.14 | 0.39 | 0.05* | 230 (96, 364) | 724 (−299, 1746) | 0.34 | 0.13 | 0.51 |
| IL-6 | 0.88 [0.46–1.29] | 1.82 [1.82-1.82] | 0.26 | 0.26 | 0.22 | 1.13 (0.70, 1.56) | 3.50 (0.23, 6.77) | 0.16 | 0.31 | 0.10 | |
| sTNF-RI | 927 [769–1091] | 1017 [1017-1017] | 0.57 | 0.25 | 0.23 | 976 (845, 1106) | 917 (−79, 1914) | 0.91 | 0.24 | 0.21 | |
| sTNF-RII | 3978 [3181–4826] | 4761 [4761-4761] | 0.49 | 0.46 | 0.02* | 4198 (3654, 4741) | 5562 (1419, 9704) | 0.51 | 0.42 | 0.02* | |
| sCD40L | 2213 [1680–3109] | 3264 [3264-3264] | 0.43 | 0.40 | 0.05* | 2934 (1915, 3952) | 403 (−7366, 8171) | 0.52 | 0.36 | 0.05 | |
|
| |||||||||||
| COC users | MCP-1 | 153 [111–189] | 203 [175–317] | 0.04* | 0.23 | 0.31 | 166 (101, 231) | 233 (190, 276) | 0.11 | 0.29 | 0.14 |
| IL-6 | 0.45 [0.37–0.78] | 0.76 [0.47–1.16] | 0.05* | 0.39 | 0.07 | 0.59 (0.09, 1.09) | 0.97 (0.65, 1.29) | 0.22 | 0.52 | <0.01* | |
| sTNF-RI | 780 [667–954] | 1087 [822–1324] | 0.04* | 0.25 | 0.25 | 869 (625, 1112) | 1007 (850, 1163) | 0.37 | 0.46 | 0.01* | |
| sTNF-RII | 4573 [3518–5399] | 4180 [3652–4554] | 0.91 | −0.05 | 0.81 | 4339 (3516, 5162) | 4236 (3708, 4764) | 0.84 | 0.04 | 0.86 | |
| sCD40L | 4674 [2375–5773] | 5799 [3062–7385] | 0.34 | 0.28 | 0.19 | 3417 (943, 5891) | 6184 (4596, 7772) | 0.08 | 0.16 | 0.40 | |
|
| |||||||||||
| CVC users | MCP-1 | 172 [166–235] | 194 [122–230] | 0.91 | 0.02 | 0.94 | 189 (132, 246) | 190 (144, 236) | 0.99 | −0.02 | 0.94 |
| IL-6 | 0.72 [0.55–1.38] | 0.83 [0.53–1.28] | 0.97 | −0.25 | 0.39 | 1.11 (0.59, 1.62) | 0.92 (0.51, 1.33) | 0.57 | 0.14 | 0.55 | |
| sTNF-RI | 616 [534–791] | 805 [660–1040] | 0.09 | −0.03 | 0.91 | 696 (476, 916) | 854 (678, 1029) | 0.27 | 0.37 | 0.12 | |
| sTNF-RII | 3725 [2531–5640] | 4940 [3754–5416] | 0.39 | 0.03 | 0.91 | 4529 (3404, 5653) | 4394 (3494, 5294) | 0.85 | 0.40 | 0.09 | |
| sCD40L | 2539 [1695–3582] | 3101 [1737–3734] | 0.73 | −0.17 | 0.57 | 3528 (1846, 4671) | 2642 (1512, 3772) | 0.49 | 0.10 | 0.69 | |
Note: a P value of <0.05 is indicated by ∗. Multivariate and partial Spearman correlation analyses adjusted for age, race, alcohol consumption, regular sleeping habit, and family history of CVD and stroke. ¶There was only 1 subject in the nonusers group whose CRP ≥ 3.